707 related articles for article (PubMed ID: 17340127)
1. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
2. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
3. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
5. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Heyliger SO; Jackson C; Rice KC; Rothman RB
Synapse; 1999 Dec; 34(4):256-65. PubMed ID: 10529720
[TBL] [Abstract][Full Text] [Related]
6. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
7. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.
Gray AC; White PJ; Coupar IM
Br J Pharmacol; 2005 Mar; 144(5):687-94. PubMed ID: 15678085
[TBL] [Abstract][Full Text] [Related]
9. Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses.
Yuan CS; Foss JF
Neuropharmacology; 1999 Mar; 38(3):425-32. PubMed ID: 10219980
[TBL] [Abstract][Full Text] [Related]
10. Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.
Yekkirala AS; Kalyuzhny AE; Portoghese PS
ACS Chem Neurosci; 2010 Feb; 1(2):146-54. PubMed ID: 22816017
[TBL] [Abstract][Full Text] [Related]
11. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
12. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
[TBL] [Abstract][Full Text] [Related]
13. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists.
Cassel JA; Daubert JD; DeHaven RN
Eur J Pharmacol; 2005 Sep; 520(1-3):29-36. PubMed ID: 16165125
[TBL] [Abstract][Full Text] [Related]
14. Relationship between inhibitory effect of endogenous opioid via mu-receptors and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum.
Nishiwaki H; Saitoh N; Nishio H; Takeuchi T; Hata F
Jpn J Pharmacol; 1998 Aug; 77(4):279-86. PubMed ID: 9749928
[TBL] [Abstract][Full Text] [Related]
15. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
16. Characterization of kappa and delta opioid receptors in isolated organs by using type/subtype selective agonists and antagonists.
Makó E; Rónai AZ
Med Sci Monit; 2001; 7(3):350-6. PubMed ID: 11386008
[TBL] [Abstract][Full Text] [Related]
17. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
18. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
19. Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene.
Maldonado R; Severini C; Matthes HW; Kieffer BL; Melchiorri P; Negri L
Br J Pharmacol; 2001 Apr; 132(7):1485-92. PubMed ID: 11264242
[TBL] [Abstract][Full Text] [Related]
20. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
